Drug Trial Radar · NCT06879717
A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients
Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Apr 22, 2025
Primary completion
Jan 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- iOncturaIndustry
- Sponsor type
- Industry
- First posted
- Mar 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn how roginolisib works in combination with dostarlimab with or without docetaxel in adult patients with advanced non small-cell lung cancer. The main questions it aims to answer are: To compare across the treatment arms the proportion of patients with a reduction in Treg cells To evaluate the safety and tolerability of roginolisib plus dostarlimab, with or without docetaxel
Conditions
- Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Advanced Non Squamous NSCLC
Interventions
roginolisibDrug
tablet, 40mg tablet strength
DostarlimabDrug
500 mg administered as IV infusion
DocetaxelDrug
75 mg/m2 administered over 1 hour as IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE V5Time frame: On Day 1 and Day 15 of Cycle 1; Day 1 of Cycle 2 onwards. Each cycle is 21 days
- To compare across treatment arms the proportion of patients with a reduction in peripheral blood Tregs (for example as defined by CD4+CD25+CD127- expression)Time frame: On Day 1 of each Cycle. Cycle length is 21 days
- Number of Participants With changes in laboratory parametersTime frame: On Day 1and Day 15 of Cycle 1; Day 1 of Cycle 2 onwards. Each cycle is 21 days
- Number of Participants with Changes in ECG from baselineTime frame: On Day 1 and Day 15 of Cycle 1; Day 1 of Cycle 2 onwards. Each cycle is 21 days
- Number of Participants With Change on Physical Examination from BaselineTime frame: On Day 1and Day 15 of Cycle 1; Day 1 of Cycle 2 onwards. Each cycle is 21 days
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
Antwerp University Hospital
Antwerp, Belgium
AZ Delta VZW
Roeselare, Belgium
Istituto Romagnolo per lo studio dei Tumori "Dino Amadori"
Meldola, Forlì-Cesena, Italy
Humanitas University, Department of Medical Oncology
Rozzano, Milan, Italy
Institut Català d'Oncologia Hospitalet
Barcelona, Spain
Hospital Universitari Son Espases
Palma, Spain
Hospital Universitario y Politécnico La Fe
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.